Wells Fargo
ALDX icon

Wells Fargo’s Aldeyra Therapeutics ALDX Stock Holding History

Wells Fargo’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,000
Closed -$15.5K – 7169
2025
Q4 		$15.5K Buy
+3,000
New +$15.4K ﹤0.01% 5856

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wells Fargo's ALDX Position: Q1 2026 in Review

Wells Fargo reduced its Aldeyra Therapeutics (ALDX) stake by 48% in Q1 2026, selling an estimated $773K and leaving 189,729 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #4395.

Wells Fargo first reported a position in ALDX in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.85M in Q2 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Wells Fargo held 189,729 shares of Aldeyra Therapeutics worth $321K as of Q1 2026.
  • Wells Fargo sold 176,440 Aldeyra Therapeutics shares in Q1 2026, an estimated $773K.
  • Aldeyra Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4395 holding.
  • Wells Fargo first reported a position in Aldeyra Therapeutics in Q4 2017 and has held it in 34 quarters since.
  • Wells Fargo's Aldeyra Therapeutics position peaked at $2.85M in Q2 2023.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.